Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
lung diseases
MeSH D008171 - lung diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D012140:
Respiratory tract diseases
50 Companies
6 Drugs
$
Success rate
D008171:
Lung diseases
3 Companies
2 Drugs
$
Success rate
D001261:
Pulmonary atelectasis
0 Companies
0 Drugs
Success rate
D003074:
Solitary pulmonary nodule
0 Companies
0 Drugs
Success rate
D003550:
Cystic fibrosis
34 Companies
15 Drugs
$
Success rate
D006469:
Hemoptysis
0 Companies
0 Drugs
Success rate
D006976:
Pulmonary hypertension
101 Companies
21 Drugs
$
Success rate
D008169:
Lung abscess
0 Companies
0 Drugs
Success rate
D008172:
Fungal lung diseases
0 Companies
0 Drugs
Success rate
D008173:
Obstructive lung diseases
53 Companies
9 Drugs
$
Success rate
D008174:
Parasitic lung diseases
0 Companies
0 Drugs
Success rate
D008175:
Lung neoplasms
57 Companies
27 Drugs
$
Success rate
D011014:
Pneumonia
69 Companies
20 Drugs
$
Success rate
D011649:
Pulmonary alveolar proteinosis
0 Companies
0 Drugs
Success rate
D011654:
Pulmonary edema
57 Companies
5 Drugs
$
Success rate
D011655:
Pulmonary embolism
66 Companies
19 Drugs
$
Success rate
D011657:
Pulmonary eosinophilia
1 Company
1 Drug
$
Success rate
D011668:
Pulmonary veno-occlusive disease
0 Companies
0 Drugs
Success rate
D012128:
Respiratory distress syndrome
49 Companies
5 Drugs
$
Success rate
D012587:
Scimitar syndrome
0 Companies
0 Drugs
Success rate
D014397:
Pulmonary tuberculosis
147 Companies
23 Drugs
$
Success rate
D015615:
Congenital cystic adenomatoid malformation of lung
0 Companies
0 Drugs
Success rate
D016726:
Pulmonary plasma cell granuloma
0 Companies
0 Drugs
Success rate
D017563:
Interstitial lung diseases
0 Companies
0 Drugs
Success rate
D019568:
Hyperlucent lung
0 Companies
0 Drugs
Success rate
D019896:
Alpha 1-antitrypsin deficiency
0 Companies
0 Drugs
Success rate
D020065:
Hepatopulmonary syndrome
0 Companies
0 Drugs
Success rate
D055370:
Lung injury
0 Companies
0 Drugs
Success rate
D056586:
Acute chest syndrome
0 Companies
0 Drugs
Success rate
D000097545:
Pulmonary hemosiderosis
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Roche
Pirfenidone
Esbriet
2011-02-27
$749.525 M
Y2022
Viatris
Pirfenidone
Pirfenidone Viatris
2023-01-10
Clinical Trials
Historical Success Rate
Phase 1
75
%
21/28
Phase 2
54
%
37/69
Phase 3
8
%
7/85
Approved:
1
Overall Success rate:
3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
CSL Behring
.alpha.1-proteinase inhibitor human
Roche
Pirfenidone
,
Transplatin
,
Albumin
,
Antithrombin iii
,
Retinol
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use